{"data":{"ModuleTitle":{"label":"Module Title","value":"Company Description"},"CompanyName":{"label":"Company Name","value":"Fennec Pharmaceuticals Inc."},"Symbol":{"label":"Symbol","value":"FENC"},"Address":{"label":"Address","value":"68 TW ALEXANDER DRIVE,PO BOX 13628, RESEARCH TRIANGLE PARK, North Carolina, 27709, United States"},"Phone":{"label":"Phone","value":"+1 919 636-4530"},"Industry":{"label":"Industry","value":"Biotechnology: Biological Products (No Diagnostic Substances)"},"Sector":{"label":"Sector","value":"Health Care"},"Region":{"label":"Region","value":"North America"},"CompanyDescription":{"label":"Company Description","value":"Fennec Pharmaceuticals Inc is a clinical-stage biotechnology company. It is primarily engaged in research and development activities. The company is developing Sodium Thiosulfate (STS), a chemo-protectant against hearing loss associated with platinum-based chemotherapy. Its lead product candidate is PEDMARK which is sodium thiosulfate in a novel formulation for the prevention of cisplatin induced hearing loss, or ototoxicity in children."},"CompanyUrl":{"label":"Company Url","value":"https://www.fennecpharma.com"},"KeyExecutives":{"label":"Key Executives","value":[{"name":"Jeffrey S Hackman","title":"Chief Executive Officer & Director"},{"name":"Pierre S. Sayad","title":"Chief Medical Officer"}]}},"message":null,"status":{"rCode":200,"bCodeMessage":null,"developerMessage":null}}